Inotuzumab after transplant for CD22-positive leukemia
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial studies inotuzumab ozogamicin, a leukemia-targeting medicine, given after an allogeneic stem cell transplant. It’s for people with CD22-positive acute lymphoblastic leukemia (ALL) to help prevent relapse and improve outcomes after transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have CD22-positive acute lymphoblastic leukemia (ALL).
- You had an allogeneic stem cell transplant for ALL from any donor type.
- You are between 40 and 100 days after transplant, and you must start the first dose by day 100.
- You must have one of these situations after transplant: minimal residual disease within 45 days, 2nd or 3rd remission, reduced-intensity treatment, relapse/refractory, Philadelphia-like ALL, or lymphoid blast phase of CML.
- Your donor cells are present in the blood (donor chimerism); the trial uses a higher cutoff for Phase 2.
- Your body is strong enough for treatment: ECOG is below the limits, blood counts are adequate (ANC > 1,000 for 3 days and platelets stay >50,000 for 7 days), and you can follow the visit schedule.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a drug called inotuzumab can help prevent leukemia from returning after you have had a stem cell transplant (also called a bone marrow transplant). The study is for adults with a type of leukemia that is considered high-risk, and the drug is given after transplant to try to keep the cancer in remission.
This trial studies inotuzumab, a targeted cancer drug, for people whose B-cell ALL has returned at a very low level after a bone-marrow or stem-cell transplant. If you qualify, it may help push the leukemia back under control after transplant.
This trial tests a drug called InO (inotuzumab ozogamicin) with or without donor white blood cells (DLI) for people whose B-ALL or LBL has returned after a stem cell transplant. The goal is to see if this treatment helps control the cancer with manageable side effects.
This Phase 2 trial tests a treatment strategy for newly diagnosed Ph+ B-cell acute lymphoblastic leukemia (ALL) that avoids traditional chemotherapy during the early “induction” phase, using inotuzumab ozogamicin instead. If it works, it could help control the leukemia while reducing exposure to chemotherapy early on.
This Phase 2 study tests inotuzumab ozogamicin (InO), a cancer medicine, in children aged 1 to under 18 with a first relapse of ALL. It aims to find out how well and safely the medicine works when the leukemia comes back early.
This early-phase trial studies how well a targeted drug (inotuzumab ozogamicin) combined with chemotherapy treats acute lymphoblastic leukemia (ALL). It may help people with newly diagnosed ALL who may not tolerate standard intensive chemotherapy, especially older adults.
Hear when a new Acute Lymphocytic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.